The long-term effects of weight loss injections: what the evidence actually shows

The biggest misconception: that stopping the injection keeps the weight off

A lot of people come to these medicines expecting a fixed course, take the injections for six months, lose the weight, move on. It's an understandable assumption, and it's worth setting it down gently rather than letting it shape an expectation that leads to disappointment.

What the trial evidence shows is almost the opposite. In the STEP 1 trial of semaglutide 2.4mg, participants who stopped taking the medicine after 68 weeks regained, on average, about two thirds of the weight they had lost within the following year. Similar patterns have been observed with tirzepatide. The likely explanation is biological: GLP-1 and GIP receptor agonists work partly by suppressing appetite signals that the brain reinstates when the medicine leaves the body. The underlying physiology of obesity doesn't simply reset.

This isn't a reason to avoid these medicines. It is a reason to go in with accurate expectations and to treat weight management as an ongoing conversation with your prescriber rather than a one-off course. The long-term picture for weight loss injections is more nuanced than headlines often suggest, and understanding it upfront is the most useful thing a person can do before starting.

As a class of medicines, they work best when paired with genuine dietary and activity changes that can be sustained independently. That combination is what the clinical trials required of participants, and it is what UK licensing reflects.

Health effects that build with sustained weight reduction

For people who stay on treatment and maintain meaningful weight loss, the downstream health signals are genuinely encouraging. Blood pressure tends to fall. Fasting blood glucose and HbA1c improve, which matters enormously for anyone with prediabetes or early type 2 diabetes. Cholesterol profiles shift in a favourable direction. Obstructive sleep apnoea, a condition strongly linked to excess weight, often improves significantly.

The NICE appraisal of tirzepatide (TA1026) drew on a body of evidence that included these metabolic endpoints, not just weight figures, when concluding that tirzepatide is cost-effective for people with a BMI of 35 or above and at least one weight-related condition. The improvements in those conditions were part of the case.

For semaglutide specifically, the medicine has also received UK authorisation to reduce the risk of major cardiovascular events in eligible adults, a recognition, rooted in trial data, that sustained weight management with this class of medicine reaches beyond the scales. You can read more about what weight loss injections do to the body across different organ systems.

None of this is a guarantee. Individual responses vary considerably. A prescriber reviews each case on its own terms, and that clinical picture (not a headline percentage) is what guides the decision to continue or adjust treatment.

Side effects over time: what tends to settle and what can persist

The side-effect profile of these medicines is well characterised now. Gastrointestinal symptoms (nausea, loose stools, reflux, occasional vomiting) are the most commonly reported, and they tend to be front-loaded: most pronounced in the first few weeks of a new dose and quieter after that. For the majority of people, the GI picture improves substantially once the body acclimatises.

A smaller proportion of people experience persistent nausea or discomfort throughout treatment. That's worth knowing in advance, because it can affect how people eat and whether they maintain adequate protein and hydration, both of which matter during sustained weight loss. The NHS medicines page for tirzepatide sets out the full list of reported effects alongside guidance on when to seek medical help.

On the more serious end: the MHRA's January 2026 Drug Safety Update flagged acute pancreatitis as an infrequent but known risk with GLP-1 medicines. Severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention rather than waiting to see if it settles. Anyone experiencing that should call 111 or go to A&E. Suspected side effects can be reported directly through the MHRA Yellow Card scheme.

Because these medicines are still relatively new at population scale, their Black Triangle status means ongoing surveillance. That's a feature of responsible pharmacovigilance, not a signal of unusual danger, but it does mean the long-term picture continues to develop as real-world data accumulates. Keeping in touch with your prescriber and flagging anything unexpected is the right approach throughout treatment. If you want to understand what side effects taking weight loss injections can involve, including how commonly they occur and which ones tend to persist, our dedicated page covers the detail, and you can also read about how the side effect profile of weight loss injections can change over the longer term as the body adapts to ongoing treatment.

Thinking about stopping, switching or continuing: a conversation for your prescriber

People reach a point where they wonder whether to keep going, reduce the dose, or try to come off the medicine gradually. This is one of the questions our prescribers hear regularly, and it doesn't have a universal answer.

NICE guidance on tirzepatide notes that continuing treatment should be reviewed if a person hasn't lost at least 5% of their body weight after six months at the highest tolerated dose. For semaglutide (Wegovy), NICE recommends treatment for a maximum of two years within a specialist weight management setting. Neither of those thresholds applies automatically, they are starting points for a clinical conversation, not automatic stop signals.

For anyone thinking about what treatment might look like for them, or for those considering transferring from another service, a free consultation with a prescriber at nume is where that conversation starts. There's no obligation, and the clinical review covers your health history, current weight, any medicines you're already taking, and what's realistic for your situation, not just whether you meet a BMI number.

If you'd like to understand the broader landscape before deciding, the weight loss treatment overview covers both injection and tablet options available in the UK. Every repeat prescription at nume is clinically re-reviewed, no automatic renewals, no software decisions.